openPR Logo
Press release

United States HER2+ Gastric Cancer Market Forecast 2024-2031: Rising Incidence, Research Investments, and Breakthrough Approvals Shaping Oncology Treatment Strategies | Astrazeneca, Genentech USA, Bristol-Myers Squibb

10-01-2025 12:08 PM CET | Health & Medicine

Press release from: DataM Intelligence 4market Research LLP

HER2+ Gastric Cancer Market

HER2+ Gastric Cancer Market

Global HER2+ Gastric Cancer Market reached with a CAGR during the forecast period 2024-2031.

The HER2+ gastric cancer market focuses on therapies for patients with gastric cancer overexpressing the HER2 protein. Targeted therapies, such as trastuzumab, along with chemotherapy, are standard treatments. Market growth is supported by increasing incidence of gastric cancer in Asia and other regions. The pipeline includes novel monoclonal antibodies, antibody-drug conjugates, and immunotherapies. Rising adoption of biomarker testing enhances patient stratification and treatment outcomes. Continued research and global approvals are driving progress in this specialized oncology segment.

πŸ“Œ Download Sample Report to Identify Emerging Deals & Opportunities in the HER2+ Gastric Cancer Market Landscape:- https://datamintelligence.com/download-sample/her2-gastric-cancer-market?rk

β˜› HER2+ Gastric Cancer Market Recent Developments 2025:

United States: Recent Industry Developments

βœ… In August 2025, Roche expanded its HER2-targeted therapies portfolio for gastric cancer in the U.S., focusing on personalized treatment options.

βœ… In July 2025, AstraZeneca launched next-generation HER2 inhibitors, supporting improved patient survival and treatment adherence.

βœ… In June 2025, Pfizer partnered with oncology centers to implement HER2+ gastric cancer clinical protocols, integrating precision medicine approaches.

Europe: Recent Industry Developments

βœ… In July 2025, Roche Europe introduced advanced HER2-targeted therapies, enhancing treatment outcomes for gastric cancer patients across EU hospitals.

βœ… In June 2025, AstraZeneca Europe expanded its gastric cancer pipeline, integrating novel HER2 inhibitors and combination therapies.

βœ… In May 2025, Amgen Europe partnered with clinics to deploy next-generation HER2+ treatment protocols, improving patient quality of life.

Japan: Recent Industry Developments

βœ… In July 2025, Takeda Pharmaceutical launched HER2-targeted therapies for gastric cancer in Japan, supporting precision oncology initiatives.

βœ… In June 2025, Chugai Pharmaceutical expanded its gastric cancer therapy portfolio, integrating HER2-targeted approaches.

βœ… In May 2025, Astellas Pharma partnered with oncology centers to implement advanced treatment protocols, improving survival outcomes.

β˜› HER2+ Gastric Cancer Market Trends:

HER2+ gastric cancer is a subtype of stomach cancer characterized by overexpression of the HER2 protein, making it responsive to targeted therapies. The market includes monoclonal antibodies, tyrosine kinase inhibitors, and combination therapies, aimed at improving survival rates and reducing tumor progression. Growth is driven by increasing gastric cancer incidence, early diagnostic improvements, and the adoption of personalized oncology treatments.

Advances in targeted therapies, antibody-drug conjugates (ADCs), and immunotherapy combinations are expanding treatment options. North America and Europe dominate due to advanced healthcare infrastructure and clinical trial activity, while Asia-Pacific is witnessing rapid growth, particularly in countries with high gastric cancer prevalence like Japan, China, and South Korea. Challenges include high therapy costs and limited access in emerging regions.

β˜› HER2+ Gastric Cancer Market Competitve Landscape:

Astrazeneca, Genentech USA, Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, Hutchison Medipharma, Linton Pharm, Shanghai Henlius Biotech, Sanofi, Pfizer, Novartis AG and among others

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

πŸ“Œ Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/her2-gastric-cancer-market

β˜› Segment Covered in the HER2+ Gastric Cancer Market:

By Therapy: Immunotherapy, Chemotherapy, Radiation Therapy, Targeted Therapy

By Stage: Stage I, Stage II, Stage III, Stage IV

By End User: Hospitals, Speciality Clinics, Ambulatory Surgical Centers, Others

β˜› This Report Includes:

βœ” Comprehensive go-to-market strategies with actionable insights.

βœ” Unbiased evaluation of overall market performance.

βœ” Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

βœ” Tailored regional and country-level reports with detailed localized analysis available on request.

βœ” Identification of niche segments and high-growth regions presenting strong opportunities.

βœ” Accurate regional forecasts using both top-down and bottom-up approaches.

πŸ“Œ Get Corporate Access to Live HER2+ Gastric Cancer Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=her2-gastric-cancer-market

β˜› Regional Analysis for HER2+ Gastric Cancer Market:

β‡₯ North America (U.S., Canada, Mexico)

β‡₯ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

β‡₯ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

β‡₯ South America (Colombia, Brazil, Argentina, Rest of South America)

β‡₯ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

β˜› Frequently asked questions:

➠ What is the global sales, production, consumption, import, and export value of the HER2+ Gastric Cancer Market?
➠ Who are the key global manufacturers, and what is their operational performance?
➠ What are the major opportunities and threats in the global HER2+ Gastric Cancer Market?
➠ Which product types or end-users show the most growth potential and market share?
➠ What challenges and constraints are impacting the HER2+ Gastric Cancer Market?
➠ What sales, marketing, and distribution channels are used globally?

πŸ“Œ Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

β˜› Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

βœ… Competitive Landscape
βœ… Sustainability Impact Analysis
βœ… KOL / Stakeholder Insights
βœ… Unmet Needs & Positioning, Pricing & Market Access Snapshots
βœ… Market Volatility & Emerging Risks Analysis
βœ… Quarterly Industry Report Updated
βœ… Live Market & Pricing Trends
βœ… Import-Export Data Monitoring

β˜› Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release United States HER2+ Gastric Cancer Market Forecast 2024-2031: Rising Incidence, Research Investments, and Breakthrough Approvals Shaping Oncology Treatment Strategies | Astrazeneca, Genentech USA, Bristol-Myers Squibb here

News-ID: 4205466 • Views: …

More Releases from DataM Intelligence 4market Research LLP

United States Bioinformatics Services Market Forecast 2024-2031: Increasing Adoption in Clinical R&D, Pharmaceutical Outsourcing, and Expansion of Cloud-Based Genomics Platforms | Illumina, Inc., PerkinElmer Inc., Premier Biosoft
United States Bioinformatics Services Market Forecast 2024-2031: Increasing Adop …
Bioinformatics Services Market is valued at a significant CAGR during the forecast period (2024-2031). The bioinformatics services market provides computational tools and expertise for managing, analyzing, and interpreting biological data. It plays a critical role in genomics, proteomics, drug discovery, and precision medicine. Market growth is fueled by the explosion of sequencing data and the need for advanced analytics. Cloud computing, AI, and big data integration are enhancing bioinformatics capabilities. Collaborations…
United States Generalized Pustular Psoriasis Market Size, Share, Growth Trends, and Forecast Analysis (2024-2031) - Biologics, Targeted Therapies, and Emerging Treatment Innovations | Bristol Myers Squibb, UCB, Inc, Pfizer Inc.
United States Generalized Pustular Psoriasis Market Size, Share, Growth Trends, …
Generalized Pustular Psoriasis Market is valued at a significant CAGR during the forecast period (2024-2031). The generalized pustular psoriasis (GPP) market focuses on therapies for this rare, severe form of psoriasis characterized by widespread pustules and systemic symptoms. Treatment options include systemic drugs, biologics, and emerging targeted therapies. Rising prevalence of autoimmune skin diseases and increased awareness drive market growth. Recent approvals of biologics targeting IL-36 pathways are transforming the treatment…
Next-Generation Molecular Biosensors Market: AI-Integrated, Wearable, and Point-of-Care Devices Driving Growth 2024-2031 | Abbott Laboratories, Nova Biomedical, Siemens Healthineers AG
Next-Generation Molecular Biosensors Market: AI-Integrated, Wearable, and Point- …
The Molecular Biosensors Market is valued at a significant CAGR during the forecast period (2024-2031). The molecular biosensors market includes devices that detect biological molecules using biochemical reactions to provide rapid, sensitive analysis. They are widely applied in medical diagnostics, environmental monitoring, food safety, and biopharma research. Market demand is fueled by rising incidences of infectious and chronic diseases, driving point-of-care diagnostics. Integration with nanotechnology and microfluidics is enhancing sensitivity and…
United States Medical Videoscope Market Insights: Minimally Invasive Surgery and Advanced Imaging Devices | Clarus Medical, Ambu, ATMOS MedizinTechnik GmbH & Co. KG
United States Medical Videoscope Market Insights: Minimally Invasive Surgery and …
The Medical Videoscope Market is valued at a significant CAGR during the forecast period (2024-2031). The medical videoscope market covers advanced endoscopic imaging devices that provide high-resolution video visualization inside the body during diagnostic and surgical procedures. They are widely used in gastroenterology, urology, pulmonology, and ENT specialties. Rising demand stems from the growing preference for minimally invasive surgeries. Market growth is fueled by technological advancements such as 4K imaging, fluorescence,…

All 5 Releases


More Releases for HER2

Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics. What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period? Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period. Global HER2 Inhibitors Market Scope and Market Size The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis. Although more drug…
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain. Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report: β€’ DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with…